- published: 05 Aug 2014
- views: 60553
Create your page here
Thursday, 10 November 2016
back to playlist
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Arlene Sharpe, M.D., Ph.D., of Harvard Medical School; Gordon Freeman, Ph.D., of Dana-Farber Cancer Institute; Tasuku Honjo, M.D., Ph.D., of Kyoto University School of Medicine; and Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute. Photos of Dr. Chen courtesy of Harold Shapiro.
- published: 06 Jan 2015
- views: 22619
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials for metastatic melanoma at the 2013 Melanoma Education Symposium hosted by The Angeles Clinic Foundation and AIM at Melanoma
- published: 21 Jul 2013
- views: 16812
www.phenopath.com
Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway” at 8:00AM (PST) on Thursday, May 5, 2016.
Listen to the webinar and learn about:
- Mechanisms of PD-1/PD-L1 interactions and the principle behind the use of PD-1 and PD-L1 inhibitors
- How data is supporting the use of PD-L1 Immunohistochemical testing in predicting drug response
- The different Immunohistochemical assays currently available to assess PD-L1 expression and their challenges and limitations
- Development and testing the analytical performance of your PD-L1 assay with precisely defined external controls
Check http://phenopath.com/uploads/pdf/pd-l1-22c3-28-8-e1l3n.pdf for more information about anti-PD-L1 antibodies 22C3, 28-8, and E1L3N algorithm.
- published: 27 May 2016
- views: 666
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
- published: 18 Mar 2016
- views: 1450
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is composed of presentations from though leaders and clinical investigators in melanoma on current and controversial topics in the field and new scientific leads from the bench to the clinic. Follow along to learn about new screening and staging modalities, emerging new management approaches, and clinical trial updates from some of the world's leading investigators in melanoma.
Earn accreditation for this activity at the following location:
http://elc.imedex.com/elc/activity-search.aspx?search=6917
© 2013 Imedex, LLC.
- published: 30 Sep 2013
- views: 11185
Anti–PD-1/PD-L1 therapy of human cancer:
PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
- published: 01 Apr 2016
- views: 880
- Loading...
-
4:00Cancer Immunotherapy - PD-1 and PD-L1
Cancer Immunotherapy - PD-1 and PD-L1Cancer Immunotherapy - PD-1 and PD-L1
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy. -
3:40Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor ImmunologyDiscovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Arlene Sharpe, M.D., Ph.D., of Harvard Medical School; Gordon Freeman, Ph.D., of Dana-Farber Cancer Institute; Tasuku Honjo, M.D., Ph.D., of Kyoto University School of Medicine; and Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute. Photos of Dr. Chen courtesy of Harold Shapiro. -
6:08PD-1, PD-L1 role in immune system inhibition
PD-1, PD-L1 role in immune system inhibition -
3:30PD-L1/PD-1 Pathway: A Security Checkpoint
PD-L1/PD-1 Pathway: A Security Checkpoint -
34:37Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhDImmunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials for metastatic melanoma at the 2013 Melanoma Education Symposium hosted by The Angeles Clinic Foundation and AIM at Melanoma -
57:38PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
www.phenopath.com Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway” at 8:00AM (PST) on Thursday, May 5, 2016. Listen to the webinar and learn about: - Mechanisms of PD-1/PD-L1 interactions and the principle behind the use of PD-1 and PD-L1 inhibitors - How data is supporting the use of PD-L1 Immunohistochemical testing in predicting drug response - The different Immunohistochemical assays currently available to assess PD-L1 expression and their challenges and limitations - Development and testing the analytical performance of your PD-L1 assay with precisely defined external controls Check http://phenopath.com/uploads/pdf/pd-l1-22c3-28-8-e1l3n.pdf for more information about anti-PD-L1 antibodies 22C3, 28-8, and E1L3N algorithm. -
1:24Anti–PD-1/PD-L1 therapy of human cancer
Anti–PD-1/PD-L1 therapy of human cancerAnti–PD-1/PD-L1 therapy of human cancer
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. -
26:40The basic biology of PD-1/PD-L1
The basic biology of PD-1/PD-L1The basic biology of PD-1/PD-L1
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is composed of presentations from though leaders and clinical investigators in melanoma on current and controversial topics in the field and new scientific leads from the bench to the clinic. Follow along to learn about new screening and staging modalities, emerging new management approaches, and clinical trial updates from some of the world's leading investigators in melanoma. Earn accreditation for this activity at the following location: http://elc.imedex.com/elc/activity-search.aspx?search=6917 © 2013 Imedex, LLC. -
1:21Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
Anti–PD-1/PD-L1 therapy of human cancer: PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. -
9:29[CF] P.D. #1 - O COMEÇO !
[CF] P.D. #1 - O COMEÇO !
-
Cancer Immunotherapy - PD-1 and PD-L1
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.
published: 05 Aug 2014 -
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Arlene Sharpe, M.D., Ph.D., of Harvard Medical School; Gordon Freeman, Ph.D., of Dana-Farber Cancer Institute; Tasuku Honjo, M.D., Ph.D., of Kyoto University School of Medicine; and Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute. Photos of Dr. Chen courtesy of Harold Shapiro.
published: 06 Jan 2015 -
-
-
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials for metastatic melanoma at the 2013 Melanoma Education Symposium hosted by The Angeles Clinic Foundation and AIM at Melanoma
published: 21 Jul 2013 -
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
www.phenopath.com Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway” at 8:00AM (PST) on Thursday, May 5, 2016. Listen to the webinar and learn about: - Mechanisms of PD-1/PD-L1 interactions and the principle behind the use of PD-1 and PD-L1 inhibitors - How data is supporting the use of PD-L1 Immunohistochemical testing in predicting drug response - The different Immunohistochemical assays currently available to assess PD-L1 expression and their challenges and limitations - Development and testing the analytical performance of your PD-L1 assay with precisely defined external controls Check http://phenopath.com/uploads/pdf/pd-l1-22c3-28-8-e1l3n.pdf for more information about anti-PD-L1 antibodi...
published: 27 May 2016 -
Anti–PD-1/PD-L1 therapy of human cancer
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
published: 18 Mar 2016 -
The basic biology of PD-1/PD-L1
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is composed of presentations from though leaders and clinical investigators in melanoma on current and controversial topics in the field and new scientific leads from the bench to the clinic. Follow along to learn about new screening and staging modalities, emerging new management approaches, and clinical trial updates from some of the world's leading investigators in melanoma. Earn accreditation for this activity at the following location: http://elc.imedex.com/elc/activity-search.aspx?search=6917 © 2013 Imedex, LLC.
published: 30 Sep 2013 -
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
Anti–PD-1/PD-L1 therapy of human cancer: PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally consi...
published: 01 Apr 2016 -
Cancer Immunotherapy - PD-1 and PD-L1
- Order: Reorder
- Duration: 4:00
- Updated: 05 Aug 2014
- views: 60553
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immun...
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.
wn.com/Cancer Immunotherapy Pd 1 And Pd L1
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our immune system through PD-L1, PD-1, and B7.1 interactions. A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.
- published: 05 Aug 2014
- views: 60553
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
- Order: Reorder
- Duration: 3:40
- Updated: 06 Jan 2015
- views: 22619
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkp...
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Arlene Sharpe, M.D., Ph.D., of Harvard Medical School; Gordon Freeman, Ph.D., of Dana-Farber Cancer Institute; Tasuku Honjo, M.D., Ph.D., of Kyoto University School of Medicine; and Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute. Photos of Dr. Chen courtesy of Harold Shapiro.
wn.com/Discovering The Pd 1 Checkpoint Winners Of The 2014 William B. Coley Award For Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Arlene Sharpe, M.D., Ph.D., of Harvard Medical School; Gordon Freeman, Ph.D., of Dana-Farber Cancer Institute; Tasuku Honjo, M.D., Ph.D., of Kyoto University School of Medicine; and Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute. Photos of Dr. Chen courtesy of Harold Shapiro.
- published: 06 Jan 2015
- views: 22619
PD-1, PD-L1 role in immune system inhibition
- Order: Reorder
- Duration: 6:08
- Updated: 24 Nov 2015
- views: 2514
PD-L1/PD-1 Pathway: A Security Checkpoint
- Order: Reorder
- Duration: 3:30
- Updated: 24 Oct 2014
- views: 20152
Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.
Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.
wn.com/Pd L1 Pd 1 Pathway A Security Checkpoint
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
- Order: Reorder
- Duration: 34:37
- Updated: 21 Jul 2013
- views: 16812
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials ...
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials for metastatic melanoma at the 2013 Melanoma Education Symposium hosted by The Angeles Clinic Foundation and AIM at Melanoma
wn.com/Immunotherapy Pd 1 And Beyond Melanoma Education Symposium, Patrick Ott Md Phd
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Cancer Center speaks on the future of immunotherapy and clinical trials for metastatic melanoma at the 2013 Melanoma Education Symposium hosted by The Angeles Clinic Foundation and AIM at Melanoma
- published: 21 Jul 2013
- views: 16812
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
- Order: Reorder
- Duration: 57:38
- Updated: 27 May 2016
- views: 666
www.phenopath.com
Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway...
www.phenopath.com
Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway” at 8:00AM (PST) on Thursday, May 5, 2016.
Listen to the webinar and learn about:
- Mechanisms of PD-1/PD-L1 interactions and the principle behind the use of PD-1 and PD-L1 inhibitors
- How data is supporting the use of PD-L1 Immunohistochemical testing in predicting drug response
- The different Immunohistochemical assays currently available to assess PD-L1 expression and their challenges and limitations
- Development and testing the analytical performance of your PD-L1 assay with precisely defined external controls
Check http://phenopath.com/uploads/pdf/pd-l1-22c3-28-8-e1l3n.pdf for more information about anti-PD-L1 antibodies 22C3, 28-8, and E1L3N algorithm.
wn.com/Pd 1 And Pd L1 Checkpoint Inhibitor Pathway (Webinar)
www.phenopath.com
Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Horizon Discovery) presented “PD-1 and PD-L1 Checkpoint Inhibitor Pathway” at 8:00AM (PST) on Thursday, May 5, 2016.
Listen to the webinar and learn about:
- Mechanisms of PD-1/PD-L1 interactions and the principle behind the use of PD-1 and PD-L1 inhibitors
- How data is supporting the use of PD-L1 Immunohistochemical testing in predicting drug response
- The different Immunohistochemical assays currently available to assess PD-L1 expression and their challenges and limitations
- Development and testing the analytical performance of your PD-L1 assay with precisely defined external controls
Check http://phenopath.com/uploads/pdf/pd-l1-22c3-28-8-e1l3n.pdf for more information about anti-PD-L1 antibodies 22C3, 28-8, and E1L3N algorithm.
- published: 27 May 2016
- views: 666
Anti–PD-1/PD-L1 therapy of human cancer
- Order: Reorder
- Duration: 1:24
- Updated: 18 Mar 2016
- views: 1450
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely ...
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
wn.com/Anti–Pd 1 Pd L1 Therapy Of Human Cancer
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
- published: 18 Mar 2016
- views: 1450
The basic biology of PD-1/PD-L1
- Order: Reorder
- Duration: 26:40
- Updated: 30 Sep 2013
- views: 11185
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is compos...
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is composed of presentations from though leaders and clinical investigators in melanoma on current and controversial topics in the field and new scientific leads from the bench to the clinic. Follow along to learn about new screening and staging modalities, emerging new management approaches, and clinical trial updates from some of the world's leading investigators in melanoma.
Earn accreditation for this activity at the following location:
http://elc.imedex.com/elc/activity-search.aspx?search=6917
© 2013 Imedex, LLC.
wn.com/The Basic Biology Of Pd 1 Pd L1
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting on September 13-14, 2013 in Baltimore, Maryland. This webcast is composed of presentations from though leaders and clinical investigators in melanoma on current and controversial topics in the field and new scientific leads from the bench to the clinic. Follow along to learn about new screening and staging modalities, emerging new management approaches, and clinical trial updates from some of the world's leading investigators in melanoma.
Earn accreditation for this activity at the following location:
http://elc.imedex.com/elc/activity-search.aspx?search=6917
© 2013 Imedex, LLC.
- published: 30 Sep 2013
- views: 11185
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
- Order: Reorder
- Duration: 1:21
- Updated: 01 Apr 2016
- views: 880
Anti–PD-1/PD-L1 therapy of human cancer:
PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to ...
Anti–PD-1/PD-L1 therapy of human cancer:
PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
wn.com/Anti–Pd 1 Pd L1 Therapy Of Human Cancer(With Sound Track)
Anti–PD-1/PD-L1 therapy of human cancer:
PD-L1,a 40kDa type 1 trans-membrane protein, is a PD-1 ligand that can deliver inhibitory signals to PD-1+ T-cells to suppress immune responses. PD-L1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. More specifically, therapies that inhibit the interaction between PD-L1, present on the surface of tumor or antigen-presenting cells, and PD-1, present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic.
- published: 01 Apr 2016
- views: 880
[CF] P.D. #1 - O COMEÇO !
- Order: Reorder
- Duration: 9:29
- Updated: 24 Sep 2013
- views: 77161
• Sons : http://www.4shared.com/zip/7NDsAS3m/CF_Russian.html?
• Gostou ? Like/Fav
• Quer acompanhar ? Inscreva-se
• Facebook : http://www.facebook.com/pages/...
• Sons : http://www.4shared.com/zip/7NDsAS3m/CF_Russian.html?
• Gostou ? Like/Fav
• Quer acompanhar ? Inscreva-se
• Facebook : http://www.facebook.com/pages/Stroiter/119459191591067
• Twitter : ht
wn.com/Cf P.D. 1 O Começo
back
- Playlist
- Chat
back
- Playlist
- Chat
4:00
Cancer Immunotherapy - PD-1 and PD-L1
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how ou...
published: 05 Aug 2014
Cancer Immunotherapy - PD-1 and PD-L1
Cancer Immunotherapy - PD-1 and PD-L1
- Report rights infringement
- published: 05 Aug 2014
- views: 60553
3:40
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology ...
published: 06 Jan 2015
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
- Report rights infringement
- published: 06 Jan 2015
- views: 22619
6:08
PD-1, PD-L1 role in immune system inhibition
Created by Kevin Zhang and Lee Brake
published: 24 Nov 2015
PD-1, PD-L1 role in immune system inhibition
PD-1, PD-L1 role in immune system inhibition
- Report rights infringement
- published: 24 Nov 2015
- views: 2514
3:30
PD-L1/PD-1 Pathway: A Security Checkpoint
Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the bo...
published: 24 Oct 2014
PD-L1/PD-1 Pathway: A Security Checkpoint
PD-L1/PD-1 Pathway: A Security Checkpoint
- Report rights infringement
- published: 24 Oct 2014
- views: 20152
34:37
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Dr. Patrick Ott, Assistant Orofessor of Medicine at Harvard Medical School, Dana Farber Ca...
published: 21 Jul 2013
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD
- Report rights infringement
- published: 21 Jul 2013
- views: 16812
57:38
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
www.phenopath.com
Dr. Allen M. Gown (from PhenoPath) and Dr. Farah Patell-Socha (from Hor...
published: 27 May 2016
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webinar)
- Report rights infringement
- published: 27 May 2016
- views: 666
1:24
Anti–PD-1/PD-L1 therapy of human cancer
PD-L1,a 40kDa type 1 transmembrane protein, is a PD-1 ligand that can deliver inhibitory s...
published: 18 Mar 2016
Anti–PD-1/PD-L1 therapy of human cancer
Anti–PD-1/PD-L1 therapy of human cancer
- Report rights infringement
- published: 18 Mar 2016
- views: 1450
26:40
The basic biology of PD-1/PD-L1
Drs. John M. Kirkwood and Antoni Ribas chaired the Perspectives in Melanoma XVII meeting o...
published: 30 Sep 2013
The basic biology of PD-1/PD-L1
The basic biology of PD-1/PD-L1
- Report rights infringement
- published: 30 Sep 2013
- views: 11185
1:21
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
Anti–PD-1/PD-L1 therapy of human cancer:
PD-L1,a 40kDa type 1 trans-membrane protein, is ...
published: 01 Apr 2016
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
Anti–PD-1/PD-L1 therapy of human cancer(with sound track)
- Report rights infringement
- published: 01 Apr 2016
- views: 880
9:29
[CF] P.D. #1 - O COMEÇO !
• Sons : http://www.4shared.com/zip/7NDsAS3m/CF_Russian.html?
• Gostou ? Like/Fav
• Quer...
published: 24 Sep 2013
[CF] P.D. #1 - O COMEÇO !
Cancer Immunotherapy - PD-1 and PD-L1...
Discovering the PD-1 Checkpoint: Winners of the 20...
PD-1, PD-L1 role in immune system inhibition...
PD-L1/PD-1 Pathway: A Security Checkpoint...
Immunotherapy - PD-1 and Beyond - Melanoma Educati...
PD-1 and PD-L1 Checkpoint Inhibitor Pathway (Webin...
Anti–PD-1/PD-L1 therapy of human cancer...
The basic biology of PD-1/PD-L1...
Anti–PD-1/PD-L1 therapy of human cancer(with sound...
![[CF] P.D. #1 - O COMEÇO !](http://web.archive.org./web/20161110060855/https://i.ytimg.com/vi/M3VjNGjGGzE/0.jpg)
[CF] P.D. #1 - O COMEÇO !...
-
Lyrics list:lyrics
-
Open Heart Surgery, Beth Ditto
-
Beth Ditto, Beth Ditto
Open Heart Surgery
I'll open up if you make an incision
I'll do right by you
All I ask is for your care and precision
And maybe I could pull through
You could've saved me if you'd only known better
But you so carlessly
Took me apart and put me back together
Open heart surgery
I was fine at first
Now I assume the worst
When I could overhear
The repercussions of a sad discussion
Another girl in tears
I could've saved here if I only knew better
That you so carelessly
Took her apart and put her back together
Open heart surgery
If girls like you and girls like me
Are really a dime a dozen
Why are we in such a high demand
My mother says it's just a shame you don't come around too often
Even she's begun to understand
Just let me know
What you were thinking
I find a way to get along somehow
Just let me go
Don't leave me hanging
Oh, please don't fail me now
Just take it slow
Don't let me suffer
I'm on the verge of an emergency
The final blow
Will make me tougher
Until then you will always be
A danger to me
We should've listened to our intuition
But we knew all to well
In addition to our suspicions
Only time could tell
With friends like you I get confused
Who needs enemies
We've been here too many times before
Open heart surgery
If girls like you and girls like me
Are really a dime a dozens
Why are we in such a high demand
My mother says it's just a shame you don't come around too often
Even she's begun to understand
Just let me know
What you were thinking
I find a way to get along somehow
Just let me go
Don't leave me hanging
Oh, please don't fail me now
Just take it slow
Don't let me suffer
I'm on the verge of an emergency
The final blow
Will make me tougher
Until then you will always be
A danger to me
A danger to me
Lyrics Licensed & Provided by LyricFind
Lyrics © Warner/Chappell Music, Inc.
back
[VIDEO]: Hillary Clinton Concession Speech: 'I'm Sorry We Did Not Win'
Edit WorldNews.com 09 Nov 2016
Addressing the public for the first time since privately conceding the presidential election to Donald Trump, Democratic nominee Hillary Clinton told the nation she wants to work with the president-elect and offered her help on behalf of the country, The Washington Post reported. Surrounded by running mate Virginia Sen ... "Last night, I congratulated Donald Trump and offered to work with him on behalf of our country ... This loss hurts....
back
Mexican Foreign Minister: We Will Not Pay For Border Wall
Edit WorldNews.com 09 Nov 2016
Mexico insisted it will not pay for a wall along the US border – a promise made by US president-elect Donald Trump during the just-completed US election – the country’s foreign minister said in a report on Raw Story Wednesday. "Paying for a wall is not part of our vision.” – Claudia Ruiz Massieu ... Backers argue it made the whole continent more competitive, but Trump complains it hollowed out US manufacturing.....
back
Trump Invites Israel's Netanyahu To US Meeting After Inauguration
Edit WorldNews.com 09 Nov 2016
Newly elected U.S. President Donald Trump has invited Israeli Prime Minister Benjamin Netanyahu to meet with him in the United States at the earliest convenience, The Jerusalem Post reported Wednesday.The Israeli prime minister called Trump to congratulate him on his electoral victory earlier in the day. The invitation to visit the president-elect came during that phone call, the report said....
back
[VIDEO] Barron Trump Will Be First Son To Live In White House Since JFK Jr.
Edit WorldNews.com 10 Nov 2016
Barron Trump will be America’s first son to live in the White House since John F. Kennedy Jr. in 1963, The Inquisitr reports.President-elect Donald Trump’s youngest son wasn’t old enough to join his much older siblings as a surrogate for his father’s presidential campaign in 2016, but he was at home with his mother watching the polls ... on Nov. 9 ... Kennedy Jr. back in 1963....
back
Here's the full text of Donald Trump's victory speech
Edit CNN 09 Nov 2016
(CNN)Here is the text of the speech Donald Trump delivered when he became the President-elect of the United States of America.. Thank you. Thank you very much, everybody. Sorry to keep you waiting. Complicated business. Complicated. Thank you very much. I've just received a call from Secretary Clinton. She congratulated us. It's about us. On our victory, and I congratulated her and her family on a very, very hard-fought campaign ... Read More ... Gov....
How Trump's win could impact life on Palm Beach Island
Edit WPTV 10 Nov 2016
Palm Beach PD says they are ready to work more with the Secret Service.They've been working with the agency every since Trump became the GOP nominee ... When Trump comes in, West Palm Beach PD, Palm Beach PD and Palm Beach County Sheriff's Office will join forces with the Secret Service, both by road and by water, to ensure the security of the newly elected president and his family....
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
Our initial protocol is a monotherapy study with the ability to move into combination therapy with a PD-1 antibody as quickly as possible ... So we would postulate that that is one of the blocks that would prevent PD-1 from working and essentially by removing a downstream immunosuppressive enzyme that’s keeping T-cell from activating. We would combine the PD-1 and push those tumors into responses....
VIVUS's (VVUS) CEO Seth Fischer on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
Two, the Qsymia adolescent pharmacokinetic and pharmacodynamic study, or PK, PD study enrollment completion and three, the protocol development and FDA discussion of our Qsymia adolescent, efficacy and safety study ... study, the Qsymia adolescent PK, PD study and the protocol finalization with FDA for our Qsymia adolescent efficacy and safety study....
Immune Design's (IMDZ) CEO Carlos Paya on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
It is being evaluated in soft tissue sarcoma or STS patients both as a potential monotherapy product and in combination with an anti-PD-L1 antibody ... Patients receive either G100 and low-dose radiation or G100 and low-dose radiation with a systemic anti-PD-1 antibody, Keytruda or pembrolizumab, pursuant also to a collaboration with Merck....
TASER International's (TASR) CEO Rick Smith on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
The recent Seattle PD win is a great example of the strong customer acceptance of TASER and the demonstrated performance of our platform as a key differentiator ... Seattle PD opted for a thorough product testing of the full hardware and software solution and also was made aware that certain competitor capabilities were not yet developed....
Juno Therapeutics' (JUNO) CEO Hans Bishop on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016Mylan NV (MYL) Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
Mylan NV (NASDAQ.MYL). Q3 2016 Earnings Call. November 09, 2016 4.30 pm ET. Executives. Kris King - Mylan NV. Heather M ... Analysts ... LLC ... For pegfilgrastim, the results from our Phase 3 clinical efficacy and safety study as well as our PK and PD study that supported our EU application were also presented at ESMO ... Our pre-clinical package included our PK and PD studies, demonstrating bioequivalence of our insulin glargine compared to Lantus ... LLC....
Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
Infinity Pharmaceuticals, Inc. (NASDAQ.INFI). Q3 2016 Earnings Conference Call. November 9, 2016 4.30 PM ET. Executives. Jaren Madden – Senior Director-Investor Relations and Corporate Communications. Adelene Perkins – President and Chief Executive Officer ... Additionally, today we announced an agreement with Bristol-Myers Squibb for the supply of Opdivo, a PD-1 immune checkpoint inhibitor for the combination portion of our Phase I study ... Mr ... ....
MannKind's (MNKD) CEO Matthew Pfeffer on Q3 2016 Results - Earnings Call Transcript
Edit Seeking Alpha 10 Nov 2016
MannKind Corp. (NASDAQ.MNKD) ... Executives ... Analysts ... Matt? ... At the same time, we are investing in our future clinically not only by starting our pediatric clinical studies in Q1, but also additional studies to better demonstrate the advantages of Afrezza, Afrezza’s PK and PD profile by focusing our near-term investment in the starting and titrating the product quickly and effectively with CGM and/or standardized dose titration schedules ... ....
Why is the PD running New York Times and Washington Post pieces on your front page?: Letter to the Editor
Edit Cleveland 09 Nov 2016Criticisms of WEWS broadcasters from editorial board laughable: Letter to the Editor
Edit Cleveland 09 Nov 2016Merseyside Police Pay Tribute To Police Dog Ghost Sadly Killed On Duty (Merseyside Police)
Edit Public Technologies 09 Nov 2016
Merseyside Police can confirm that one of our valued police dogs, Police Dog (PD) Ghost, died in the early hours of Tuesday morning (8th November), whilst on duty ... As part of the search of the area, PD Ghost, a German Shepherd who would have been four years-old on 19 November, and his handler, Constable Dave Bartley, were deployed to try and trace any offenders. Sadly, PD Ghost was found on the M6 motorway a short while later....
Shooting Near LA-Area Polling Site Leaves 1 Dead, 3 Injured
Edit The Wrap 09 Nov 2016
“Incident began at 202pm with reports of shots fired near Memorial Park 320 N Orange Ave,” the Azusa PD tweeted Tuesday afternoon ... They returned fire and all officers who came under fire were safe and accounted for ... “The scene is still not stable,” Azusa PD chief Steve Hunt said during a press conference at approximately 4.30 p.m. local time....
- 1
- 2
- 3
- 4
- 5
- Next page »
